Investment analysts at HC Wainwright assumed coverage on shares of Equillium (NYSE:EQ) in a research note issued on Friday, AnalystRatings.com reports. The brokerage set a “buy” rating and a $14.00 price target on the stock. HC Wainwright’s price target points to a potential upside of 154.55% from the stock’s current price.
Separately, Zacks Investment Research upgraded Flagstar Bancorp from a “hold” rating to a “buy” rating and set a $38.00 target price on the stock in a research note on Monday, July 8th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $17.75.
Shares of EQ stock opened at $5.50 on Friday. The company has a 50 day moving average of $5.98. Equillium has a twelve month low of $5.12 and a twelve month high of $19.69.
Equillium (NYSE:EQ) last announced its earnings results on Monday, May 13th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.04).
Several institutional investors and hedge funds have recently bought and sold shares of EQ. Partner Fund Management L.P. acquired a new stake in shares of Equillium in the 4th quarter valued at approximately $11,049,000. FMR LLC acquired a new stake in shares of Equillium in the 4th quarter valued at approximately $6,994,000. BlackRock Inc. acquired a new stake in shares of Equillium in the 4th quarter valued at approximately $1,756,000. Victory Capital Management Inc. lifted its holdings in shares of Equillium by 7.4% in the 1st quarter. Victory Capital Management Inc. now owns 1,323,381 shares of the company’s stock valued at $10,587,000 after buying an additional 90,792 shares during the period. Finally, Northern Trust Corp acquired a new stake in shares of Equillium in the 4th quarter valued at approximately $298,000.
Equillium Company Profile
Equillium, Inc, a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is EQ001, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis.
Featured Article: Risk Tolerance
Receive News & Ratings for Equillium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equillium and related companies with MarketBeat.com's FREE daily email newsletter.